In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods

Chun Hsing Liao, Hsiang Chi Kung, Gwo Jong Hsu, Po Liang Lu, Yung Ching Liu, Chih Ming Chen, Chun Ming Lee, Wu Sun, Tsrang Neng Jang, Ping Cherng Chiang, Yu Jen Cheng, Hsiu Chen Lin, Zhi Yuan Shi, Lih Shinn Wang, Yin Ching Chuang, Shih Ming Tsao, Chin Te Lu, Jien Wei Liu, Cheng Hua Huang, Po Ren Hsueh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A total of 393 isolates of A. baumannii were collected from patients treated at 19 teaching hospitals in Taiwan. Minimum inhibitory concentrations (MICs) and inhibitory zone diameters for tigecycline were determined by the broth microdilution method and the disk diffusion method, respectively. The MIC results were interpreted using the US FDA tigecycline susceptibility breakpoints for Enterobacteriaceae (susceptible [S] ≤2 μg/mL; intermediate [I] 4 μg/mL; resistant [R] ≥8 μg/mL). The disk diffusion results were interpreted by criteria recommended by Jones et al. (S ≥16 mm; I 13-15 mm; R ≤12 mm) and also by those recommended by the US FDA for Enterobacteriaceae (S ≥19 mm; I 15-18 mm; R ≤14 mm). The percentages of susceptible, intermediate and resistant isolates determined by the broth microdilution method were 80.9%, 12.2%, and 6.9%, respectively. The rates of susceptible, intermediate and resistant isolates by the disk diffusion method using the criteria of Jones et al. were 88.3%, 9.9% and 1.8% and using the US FDA criteria were 44.0%, 51.7% and 4.3%. Using the criteria recommended by Jones et al., the total error rate of the disk diffusion method in comparison with the broth microdilution method was 14.2% (56/393). For routine susceptibility testing of tigecycline against A. baumannii the broth microdilution method, not the disk diffusion method, should be used due to the poor correlation of results between these two methods interpreted either by the Jones et al. or US FDA criteria.

Original languageEnglish
Pages (from-to)S192-S196
JournalInternational Journal of Antimicrobial Agents
Volume32
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Keywords

  • Acinetobacter baumannii
  • Broth microdilution
  • Disk diffusion
  • Taiwan
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods'. Together they form a unique fingerprint.

  • Cite this

    Liao, C. H., Kung, H. C., Hsu, G. J., Lu, P. L., Liu, Y. C., Chen, C. M., Lee, C. M., Sun, W., Jang, T. N., Chiang, P. C., Cheng, Y. J., Lin, H. C., Shi, Z. Y., Wang, L. S., Chuang, Y. C., Tsao, S. M., Lu, C. T., Liu, J. W., Huang, C. H., & Hsueh, P. R. (2008). In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. International Journal of Antimicrobial Agents, 32(SUPPL. 3), S192-S196. https://doi.org/10.1016/S0924-8579(08)70027-X